• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.

作者信息

Böll Boris, Borchmann Peter, Topp Max S, Hänel Mathias, Reiners Katrin S, Engert Andreas, Naumann Ralph

出版信息

Br J Haematol. 2010 Feb;148(3):480-2. doi: 10.1111/j.1365-2141.2009.07963.x. Epub 2009 Oct 15.

DOI:10.1111/j.1365-2141.2009.07963.x
PMID:19863533
Abstract
摘要

相似文献

1
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.来那度胺用于难治性或多次复发的霍奇金淋巴瘤患者。
Br J Haematol. 2010 Feb;148(3):480-2. doi: 10.1111/j.1365-2141.2009.07963.x. Epub 2009 Oct 15.
2
Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma.难治性经典型霍奇金淋巴瘤患者的肿瘤flare反应及对来那度胺的反应
Am J Hematol. 2010 Jan;85(1):87-90. doi: 10.1002/ajh.21571.
3
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.来那度胺单药治疗可使复发或难治性惰性非霍奇金淋巴瘤产生持久缓解。
J Clin Oncol. 2009 Nov 10;27(32):5404-9. doi: 10.1200/JCO.2008.21.1169. Epub 2009 Oct 5.
4
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.来那度胺口服单药治疗对复发或难治性套细胞淋巴瘤患者有较高的缓解率。
Br J Haematol. 2009 May;145(3):344-9. doi: 10.1111/j.1365-2141.2009.07626.x. Epub 2009 Feb 24.
5
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.来那度胺单药治疗复发或难治性侵袭性非霍奇金淋巴瘤。
J Clin Oncol. 2008 Oct 20;26(30):4952-7. doi: 10.1200/JCO.2007.15.3429. Epub 2008 Jul 7.
6
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.一项关于来那度胺治疗预处理后复发或难治性转移性恶性黑色素瘤的多中心、随机、双盲 2/3 期研究的结果。
Cancer. 2010 Jan 1;116(1):146-54. doi: 10.1002/cncr.24686.
7
Lenalidomide in multiple myeloma.来那度胺治疗多发性骨髓瘤
Best Pract Res Clin Haematol. 2007 Dec;20(4):717-35. doi: 10.1016/j.beha.2007.09.002.
8
Successful outcome of patients with relapsed/refractor Hodgkin lymphoma treated with high dose chemotherapy at the National Adult Bone Marrow Transplant Unit at St. James's Hospital.在圣詹姆斯医院国家成人骨髓移植科接受高剂量化疗的复发/难治性霍奇金淋巴瘤患者的治疗结果
Ir Med J. 2009 Jan;102(1):26-8.
9
Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma.来那度胺作为单一药物可使难治性套细胞淋巴瘤完全缓解。
Ann Hematol. 2009 Sep;88(9):921-2. doi: 10.1007/s00277-008-0692-4. Epub 2009 Jan 13.
10
Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.复发/难治性骨髓瘤患者的管理：包含来那度胺的策略
Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. doi: 10.1053/j.seminhematol.2005.10.004.

引用本文的文献

1
Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.结节性淋巴细胞为主型霍奇金淋巴瘤：疾病生物学、风险分层和治疗的进展。
Haematologica. 2024 Nov 1;109(11):3476-3487. doi: 10.3324/haematol.2024.285903.
2
Lenalidomide with or without dexamethasone for relapsed or refractory Hodgkin lymphoma post autologous stem cell transplant.来那度胺联合或不联合地塞米松用于自体干细胞移植后复发或难治性霍奇金淋巴瘤的治疗
Blood Cell Ther. 2023 Aug 25;6(3):95-103. doi: 10.31547/bct-2023-009.
3
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
来那度胺间断和持续给药治疗复发/难治性霍奇金淋巴瘤的II期研究。
Haematologica. 2024 Mar 1;109(3):953-957. doi: 10.3324/haematol.2022.282246.
4
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.基于罗米地辛和来那度胺的治疗方案对复发/难治性淋巴瘤有效：两项包含扩展队列的I期研究的联合分析
Am J Hematol. 2021 Oct 1;96(10):1211-1222. doi: 10.1002/ajh.26288. Epub 2021 Jul 29.
5
Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series.低剂量持续使用来那度胺治疗复发或难治性经典型霍奇金淋巴瘤的多次预处理患者：一项回顾性病例系列研究
Ther Adv Hematol. 2020 Sep 26;11:2040620720947340. doi: 10.1177/2040620720947340. eCollection 2020.
6
Moving things forward in Hodgkin lymphoma.推动霍奇金淋巴瘤研究的进展。
F1000Res. 2018 Nov 13;7. doi: 10.12688/f1000research.16077.1. eCollection 2018.
7
Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma.来那度胺与塞来昔布联合治疗原发性难治性霍奇金淋巴瘤的完全缓解病例
Onco Targets Ther. 2018 Oct 8;11:6599-6603. doi: 10.2147/OTT.S175016. eCollection 2018.
8
Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience.依维莫司单药治疗难治性或复发性霍奇金淋巴瘤：巴西指定患者项目经验
Rev Bras Hematol Hemoter. 2017 Jul-Sep;39(3):216-222. doi: 10.1016/j.bjhh.2017.03.008. Epub 2017 May 11.
9
New agents in relapsed/refractory Hodgkin's lymphoma.复发/难治性霍奇金淋巴瘤的新型药物
Rev Bras Hematol Hemoter. 2017 Jul-Sep;39(3):193-196. doi: 10.1016/j.bjhh.2017.05.003. Epub 2017 May 28.
10
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.帕比司他联合来那度胺治疗复发或难治性霍奇金淋巴瘤的I/II期试验
Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):347-353. doi: 10.1016/j.clml.2017.05.008. Epub 2017 May 22.